Ceftriaxone (Ro 13-9904) was compared with other newer f3-lactam antibiotics for activity in experimental infections of mice with Enterobacteriaceae, Haemophilu influenzae, Pseudomonas aeruginosa, and gram-positive bacteria. Overall, ceftriaxone was equal or superior to cefotaxime and cefoperazone against systemic infections. All three drugs were highly potent against most organisms but were considerably less active against P. aeruginosa. However, ceftriaxone tended to be more active ihan the other two agents against 8 of the 10 P. aeruginosa strains tested. Ceftriaxone, cefmenoxime (SCE 1365), and moxalactam were all highly active against systemic infections with 16 strains of Enterobacteriaceae, whereas ceftriaxone was more active against infections with two strains of streptococci. When the drugs were administered at various time intervals before infection, ceftriaxone was superior to cefotaxime, cefmenoxime, and moxalactam. This suggested that ceftriaxone might be eliminated from mice more slowly than the other drugs. In the case of cefotaxime, this was directly confirmed by microbiological assays of plasma samples. In a murine meningitis model induced by Klebsiella penumoniae or Streptococcus pneumoniae, ceftriaxone was more active than ampicillin or cefotaxime. Ceftriaxone was more active than ampicillin, cefotaxime, piperacillin, cefamandole, or carbenicillin in a pneumococcal pneumonia model in mice. These studies indicate that ceftriaxone is a potent, broadspectrum cephalosporin with unusual pharmacokinetic properties.
Ceftriaxone (Ro 13-9904), a 2-aminothiazolyl methoxyimino cephalosporin derivative, has exhibited high orders of activity, both in vitro (1, 2, 5, 7, 11, 13, 14, 17, 18 ) and in vivo (1, 11) , against a broad spectrum of bacteria. Two other members of this chemical series, cefmenoxime (SCE 1365) (4) and cefotaxime (6) , as well as cefoperazone (T 1551) (9) and moxalactam (LY 127935) (8) , a novel 1-oxacephem, have also displayed similar potency and breadth of activity. Angehrn et aL (1) have shown that because of a more favorable pharmacokinetic profile, ceftriaxone may have advantages over these other new agents in vivo.
This report describes the results of extensive studies of the activity of ceftriasxone in several mouse models and aims at defining more clearly the potential of this new agent.
MATERIALS AND METHODS Antibiotics. Ceftriaxone, cefotaxime (HR 756) , ce- foperazone (Toyama, T 1551), cefmenoxime (Takeda), and moxalactam (Lilly, Shionogi, LY 127935, 6059-S) were supplied through the courtesy of Roche Chemical Research, BaseL Switzerland, and Nippon Roche, Japan. Ampicillin (Wyeth Laboratories, Inc.), carbeni- ciflin (Pfizer Inc.), cefamandole (Eli Lilly & Co.), and piperacillin (Lederle Laboratories) were obtained commercially. All antibiotics were dissolved in distilled water and used within 24 h of preparation.
Bacterial strains. The 75 bacterial strains used in this study (see Table 1 ) were mainly from our culture collection but also included some recent clinical isolates obtained from several hospital sources. The six group B streptococcus strains were Streptococcus agalactiae from our culture collection and types Ia-090, Ib-H36B, Ic (15) , who described the histopathological changes that accompany this experimentally produced disease. The mice, under light Metofane anesthesia, were injected intracraniaUy through the right orbital surface of the zygomatic bone (posterior corner of the right eye) with 0.03 ml of an infecting inoculum containing 100 to 1,000 LD50s. Infected mice were treated once, 1 h after infection, using a range of doses of antibiotics and numbers ofmice as described above for intraperitoneal infections. Untreated controls died within 48 to 96 h after infection. Virulence titrations were also carried out in each experiment to determine the number of LDsos in the challenge inoculum. PDsos were calculated by the method of Reed and Muench.
Experimental pneumonia. Pneumonia was induced in mice by intranasal instillation of 3 drops of an undiluted overnight culture of Streptococcuspneumoniae 6301 in Trypticase soy broth containing 5% goat serum. The challenge dose was aministered under light Metofane anesthesia with a 1.0-ml tuberculin syringe with a 22-gauge, 1-in. (2.54-cm) needle. Infected mice were treated once subcutaneously 24 h after infection.
The mice were sacrificed 48 h after infection. The lungs were removed aseptically and cultured for the presence of the organism by touching a cut surface of the lung to blood agar. Untreated controls 48 h after infection evidenced consolidation of the lungs with heavily positive cultures. Most, but not all, of the untreated controls died within 96 h after infection. Plasma levels in mice. Plasma levels of ceftriaxone and cefotaxime were determined at various times after intravenous administration of 50 mg of either antibiotic per ml dissolved in physiological saline. Blood samples were taken at each of the indicated time intervals (5, 10, 15, 20, 30, 60, 120 , and 240 min) by cardiac puncture with a heparinized syringe. The samples from five mice were pooled and centrifuged immediately. The plasma samples were deproteinized with ethanol, and the levels of ceftriaxone and cefotaxime were determined by large-plate bioassay which employed Escherichia coli strain 1346.
RESULTS
Activity of ceftriaxone, cefota3ime, and cefoperazone in systemic mouse infections and in vitro. All three drugs, ceftriaxone, cefotaxime, and cefoperazone, were highly active in vivo (PD5os, about 2 mg/kg or less) against 22 of 46 of the Enterobacteriaceae and all of the Haemophilus strains tested (Table 1) . Ceftriaxone and cefotaxime were also highly active against the six group B streptococci representative of the major serotypes (cefoperazone was not tested against these strains).
Ceftriaxone, cefotaxime, and cefoperazone were all somewhat less active, but comparable in activity (PD5os, ca. c50 mg/kg or less) against six Enterobacteriaceae and against five grampositive bacteria, including the three Staphylococcus aureus strains.
Ceftriaxone and cefotaxime exhibited generally similar activities, and both were more active than cefoperazone against 13 strains of Enterobacteriaceae: Escherichia coli 4, 387-1, and 5152; Enterobacter cloacae 9295; Serratia marcescens S714, 5805, and S4; and six of the eight Proteus strains.
Ceftriaxone was more active than either cefotaxime or cefoperazone against Escherichia coli R563, Salmonella typhi P58A, Streptococcus pyogenes 4, and Streptococcus pneumoniae 6301 and 6302.
Against the 10 Pseudomonas aeruginosa infections, the three antibiotics were considerably less active than they were against the other genera tested. Eight strains responded to ceftriaxone, whereas six strains responded to cefoperazone and three strains responded to cefotaxime at concentrations lower than 250 mg/kg. Where the antibiotics were active, PD50 values for ceftriaxone tended to be lower than for the other drugs.
There were at times wide variations in the absolute activity of the antibiotics from test to test, owing perhaps to differences in the virulence of the inoculum or the susceptibility of the mouse host. For example, although most of the PD50s for ceftriaxone in Tables 1 and 2 agree within a fourfold range, in some cases there were differences as great as 80-fold (Proteus mirabilis 2 and Providencia rettgeri ATCC 9250). Therefore, each experiment was internally controlled by testing all drugs to be compared against the same inoculum prepared from a single overnight culture with the same lot of animals.
Overall, the in vitro activities of ceftriaxone and cefotaxime were similar against the 75 strains tested (Table 1) . Both ceftriaxone and cefotaxime were more active than cefoperazone against most of the strains of Escherichia coli, Klebsiellapneumoniae, Enterobacter spp., Proteus spp., Serratia marcescens, Haemophilus influenzae, and Streptococcus spp. tested, whereas the three agents were equipotent against strains of Citrobacter spp., Salmonella spp., and Staphylococcus spp. Although none of the three agents was clearly superior against Pseudomonas aeruginosa, cefoperazone tended to be more active than the other two drugs.
The relationship between in vitro activity and in vivo activity was generally consistent in that a low MIC (<1 ,ug/ml) usually was indicative of high in vivo activity (PD50, <1 mg/kg). However, there were some exceptions. For example, Enterobacter cloacae 9295 had an MIC of 0.39 ,ug/ ml for cefoperazone, but the PD50 was >250 mg/ kg. Although ceftriaxone and cefotaxime were active in vivo against this organism, the PD5os of 51 and 24 mg/kg, respectively, were much higher than would be expected from the MIC of 0.098 ,ug/ml for both drugs. The extremely high potencies of ceftriaxone and cefotaxime against Proteus spp. strains were observed in vitro as well as in vivo.
Activity of ceftriaxone, cefmenoxime, and moxalactam in vivo and in vitro. The in vivo activity of the three agents was comparable against the 16 Enterobacteriaceae strains (Table 2) . Against Pseudomonas aeruginosa 5712, ceftriaxone and cefmenoxime were equivalent in activity, whereas moxalactam was inactive at 100 mg/kg. Against the two gram-positive bacteria, ceftriaxone was more active than cefmenoxime, whereas moxalactam was inactive at 50 mg/kg. The AiqTimICROB. AGENTS CHZMOTHZR. was adinitered immediately after infection (Table 4) . However, when the drugs were administered 4 h before infection, ceftriaxone was 90 times more active than cefmenoxime, whereas moxalactam was inactive at a dose of 50 mg/kg. When administered 8 h before infection, both cefmenoxime and moxalactam were inactive, whereas ceftriaxone was still very active. The results ofthe prophylactic studies suggested that the superior prolonged in vivo activity of ceftriaxone might be due, at least in part, to a relatively slow elimination of the drug. Plasma levels of ceftriaxone and cefotaxime in mice. The plasma concentrations of ceftriaxone after a single intravenous dose of 50 mg/kg were consistently higher than those observed with the same dose of cefotaxime throughout the first 120 min (Table 5 ). Ceftriaxone was still present 240 min after administration at a level sufficient to inhibit most of the bacterial strains used in this study, whereas cefotaxime levels were undetectable.
Bacterial meningitis. Shown in Table 6 are the results of a series of experiments in which the activity of ceftriaxone was compared with those of cefotaxime and ampicillin in mice infected intracranially with Klebsiella pneumoniae A or Streptococcus pneumoniae 6301. The activity of ceftriaxone, based on the geometric mean PD50, was 10 and 100 times greater than the activities of cefotaxime and ampicillin, respectively, against Klebsiella pneumoniae A. Against Streptococcus pneumoniae 6301, ceftriaxone was 6 and 13 times more active than cefotaxime and ampicillin, respectively. Pneumococcal pneumonia. Shown in Table  7 are the results of experiments in which the activity of ceftriaxone was compared with those The potential phamacokinetic advantage of ceftriaxone for mice suggests that the pharmacokinetics of this agent in humans might also be different than those of other cephalosporins. Recently, Seddon et al. (12) found that ceftriaxone had a mean elimination half-life of 8 h in human volunteers given 500 mg intravenously. This is considerably longer than that of any of the other newer parenteral cephems (12) .
Ceftriaxone was superior to cefotaxime and ampicillin in the experimental meningitis model of mice and also to the other f8-lactam antibiotics tested in the pneumococcal pneumonia model of mice. Since the meningitis model was based on what was shown histopathologically to be a meningitis, our results suggest that ceftriaxone penetrated the cerebrospinal fluid to control the infection. Although our data do not directly prove that ceftriaxone can penetrate cerebrospinal fluid effectively, other investigators have shown that, in another meningitis model, ceftriaxone penetrated the cerebrospinal fluid of the inflamed meninges of rabbits and effectively controlled both Escherichia coli and group B streptococcal meningitis (20th ICAAC, abstr. no 563). In the experimental pneumococcal pneumonia model, the activity of ceftriaxone was superior to ampicillin, cefotaxime, piperacillin, cefamandole, and carbenicillin, a finding which may be indicative of the potential of ceftriaxone to penetrate lung tissue.
From these results, it can be concluded that ceftriaxone is a highly active, broad-spectrum cephalosporin with interesting pharnacokinetic properties. In view of the promising in vitro and in vivo experimental results, clinical trials with ceftriaxone have been initiated. LITERATURE CITED
